OBJECTIVE: Efavirenz, an antiretroviral medicine, is extensively metabolized by cytochrome P450 2B6 (CYP2B6), UDP-glucuronosyltransferase 2B7 (UGT2B7), and CYP2A6. In this study, we investigated the association of single nucleotide polymorphisms (SNPs) in these genes with plasma efavirenz levels in Zimbabwean human immunodeficiency virus (HIV)-positive patients treated with efavirenz. METHODS: The exon regions of the CYP2B6, CYP2A6, and UGT2B7 genes were re-sequenced in 49 HIV-infected Zimbabwean patients treated with a combination therapy including efavirenz. Associations of SNPs in these three genes with efavirenz plasma concentrations 11-16 h after the administration of treatment were evaluated. RESULTS: Eight patients carrying CYP2B6*6/*18 showed the highest plasma efavirenz levels, with a fourfold higher concentration than patients who carried CYP2B6*1/*1. Patients with CYP2B6*6/*6 also showed higher efavirenz plasma concentrations than those with CYP2B6*1/*1. Among the 17 and 12 SNPs identified in CYP2A6 and UGT2B7, respectively, no SNP showed a significant association with the plasma efavirenz concentration. CONCLUSION: Although based on only a limited number of subjects, our results suggest that the CYP2B6*6 and CYP2B6*18 alleles should affect hepatic metabolic activity and elevate the systemic circulation level of efavirenz, which may lead to toxicity in Zimbabwean HIV patients.
OBJECTIVE: Efavirenz, an antiretroviral medicine, is extensively metabolized by cytochrome P450 2B6 (CYP2B6), UDP-glucuronosyltransferase 2B7 (UGT2B7), and CYP2A6. In this study, we investigated the association of single nucleotide polymorphisms (SNPs) in these genes with plasma efavirenz levels in Zimbabwean human immunodeficiency virus (HIV)-positivepatients treated with efavirenz. METHODS: The exon regions of the CYP2B6, CYP2A6, and UGT2B7 genes were re-sequenced in 49 HIV-infected Zimbabweanpatients treated with a combination therapy including efavirenz. Associations of SNPs in these three genes with efavirenz plasma concentrations 11-16 h after the administration of treatment were evaluated. RESULTS: Eight patients carrying CYP2B6*6/*18 showed the highest plasma efavirenz levels, with a fourfold higher concentration than patients who carried CYP2B6*1/*1. Patients with CYP2B6*6/*6 also showed higher efavirenz plasma concentrations than those with CYP2B6*1/*1. Among the 17 and 12 SNPs identified in CYP2A6 and UGT2B7, respectively, no SNP showed a significant association with the plasma efavirenz concentration. CONCLUSION: Although based on only a limited number of subjects, our results suggest that the CYP2B6*6 and CYP2B6*18 alleles should affect hepatic metabolic activity and elevate the systemic circulation level of efavirenz, which may lead to toxicity in Zimbabwean HIVpatients.
Authors: E Ngaimisi; S Mugusi; O M Minzi; P Sasi; K-D Riedel; A Suda; N Ueda; M Janabi; F Mugusi; W E Haefeli; J Burhenne; E Aklillu Journal: Clin Pharmacol Ther Date: 2010-09-29 Impact factor: 6.875
Authors: David W Haas; Heather J Ribaudo; Richard B Kim; Camlin Tierney; Grant R Wilkinson; Roy M Gulick; David B Clifford; Todd Hulgan; Catia Marzolini; Edward P Acosta Journal: AIDS Date: 2004-12-03 Impact factor: 4.177
Authors: L K Shipton; C W Wester; S Stock; N Ndwapi; T Gaolathe; I Thior; A Avalos; H J Moffat; J J Mboya; E Widenfelt; M Essex; M D Hughes; R L Shapiro Journal: Int J Tuberc Lung Dis Date: 2009-03 Impact factor: 2.373
Authors: Jue Wang; Anders Sönnerborg; Anders Rane; Filip Josephson; Stefan Lundgren; Lars Ståhle; Magnus Ingelman-Sundberg Journal: Pharmacogenet Genomics Date: 2006-03 Impact factor: 2.089
Authors: Jonathan L Chang; Sulggi A Lee; Alexander C Tsai; Nicholas Musinguzi; Conrad Muzoora; Bosco Bwana; Yap Boum; Jessica E Haberer; Peter W Hunt; Jeff Martin; David R Bangsberg; Deanna L Kroetz; Mark J Siedner Journal: AIDS Res Hum Retroviruses Date: 2018-08-15 Impact factor: 2.205
Authors: Phumla Z Sinxadi; Paul D Leger; Helen M McIlleron; Peter J Smith; Joel A Dave; Naomi S Levitt; Gary Maartens; David W Haas Journal: Br J Clin Pharmacol Date: 2015-05-28 Impact factor: 4.335
Authors: Keneuoe Cecilia Nthontho; Andrew Khulekani Ndlovu; Kirthana Sharma; Ishmael Kasvosve; Daniel Louis Hertz; Giacomo Maria Paganotti Journal: Pharmgenomics Pers Med Date: 2022-06-21